Screen for pre-eclampsia
AssigneeUniversity College London
InventorsMakrina Savvidou, Aroon Hingorani, Patrick Vallance, Kypros Nicolaides
Life of this patent
Estimating the term…
Abstract
It has been demonstrated that the level of asymmetric dimethylarginine (ADMA) increases in women that subsequently develop pre-eclampsia or whose fetus subsequently develops intrauterine growth restriction (IUGR) and that ADMA plays a key role in the development of maternal hypertension. Accordingly, the level of ADMA in a pregnant woman can be used to determine whether or not a pregnant woman is at risk of developing pre-eclampsia or whether or not a fetus is at risk of developing IUGR. Furthermore, antagonists of ADMA activity are useful in the inhibition or prevention of pre-eclampsia or inhibition or prevention of IUGR.
Claims28
A method of identifying whether or not a pregnant woman is at risk of developing pre-eclampsia or whether or not her fetus is at risk of developing intrauterine growth restriction (IUGR), which method comprises measuring asymmetric dimethylarginine (ADMA) in the pregnant woman and thereby determining whether or not the woman is at risk of developing pre-eclampsia or determining whether or not her fetus is at risk of developing IUGR.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An animal which is:
- (a) a non-human pregnant female animal in which pre-eclampsia has been established by administration of ADMA;
- (b) a non-human pregnant female animal in which IUGR has been established in her fetus by administration of ADMA;
- or
- (c) a non-human fetus in which IUGR has been established by administration of ADMA to a non-human female animal that is pregnant with the fetus.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.